Home › Blog › Gynaecology › AI Clinical Decision Support

Quick Answer

An AI tool earns the label evidence-based in obstetrics and gynaecology only if it passes six testable properties: citations that resolve to real documents, guideline versions that are current and dated, jurisdiction awareness (FOGSI and NCG alongside ACOG and WHO for Indian practice), explicit uncertainty when evidence conflicts, retrieval-grounded answers rather than parametric recall, and an auditable trail from question to source. Most general chatbots fail at least four of the six. The gap is architectural: a 2025 JAMIA meta-analysis found retrieval-augmented generation significantly improves LLM accuracy over baseline (pooled OR 1.35; 95 percent CI 1.19-1.53), which is why retrieval design, not model size, is the property to interrogate first.

Key Takeaways

• Evidence-based is a testable claim, not a marketing register. Six properties can be checked by any clinician in under ten minutes with three questions from their own practice.
• OBGYN stresses every property at once: guidance is multi-source (FOGSI, NCG, ICMR, WHO, ACOG, RCOG), frequently divergent by design, and revised on different cycles.
• The divergence is legitimate, not error. FOGSI resource-stratified cervical screening and the DIPSI single-step GDM protocol differ from ACOG because Indian delivery conditions differ. A tool that cannot represent both jurisdictions cannot support Indian practice.
• Grounding works when measured: guideline-as-context designs raised accuracy from 43 to 99 percent in a hepatology framework study, and eliminated hallucinations (8 percent to zero) in a 2025 radiology consultation study.
• The clinician remains the decision-maker. Decision support that behaves as an oracle rather than an evidence surface fails the audit property by definition.

Why the Definition Matters in OBGYN

Every AI product aimed at doctors now calls itself evidence-based. The phrase has become the "clinically proven" of medical software: ubiquitous, unregulated, and unfalsifiable as usually stated. We have set out what evidence-based should mean for medical AI in general terms; this article applies that standard to one specialty. For most specialties a vague evidence claim is an annoyance. For obstetrics and gynaecology it is a hazard, because the specialty combines three features that punish vague evidence claims.

First, the guidance landscape is genuinely plural. An Indian gynaecologist answers to FOGSI GCPRs, NCG resource-stratified guidance, ICMR positions, national programme protocols, and state-level operational guidelines, while also reading ACOG, RCOG, FIGO, and WHO. Second, these sources disagree on purpose: recommendations are stratified by resource setting because India’s delivery conditions range from tertiary centres to VIA-based district screening camps. Third, decisions are time-pressured and frequently irreversible; the difference between a correct and near-correct answer on magnesium sulphate dosing or a screen-and-treat threshold is measured in outcomes, not style points.

In that landscape, "our AI is trained on medical literature" is not information. What follows is a definition a clinician can test.

The Six Testable Properties, Applied to Gynaecology

1. Citations resolve. Every clinical answer should carry references a clinician can click and read. The base-model failure here is quantified: 28.6 percent of GPT-4 generated references and 91.4 percent of Bard references were hallucinated in a 471-reference comparative analysis (Chelli et al, JMIR, 2024). The specialty-level picture, how accurate general chatbots actually are on gynaecology questions, is set out in our companion article. Test it: ask for the source of a cervical screening interval and open the link.

2. Versions are current and dated. WHO cervical screening guidance, GINA-style annual revision culture, and FIGO updates mean an undated answer is an unanswerable one. A tool should state which version of a guideline it is quoting and when that version was issued. Test it: ask what changed in the most recent revision of any guideline you know well.

3. Jurisdiction awareness. The tool should know that "how do I screen for GDM" has an ACOG answer and a DIPSI answer, and should ask, or infer, which health system the clinician works in. A system that returns only the two-step protocol to an Indian medical officer fails Indian practice even while being technically accurate. This is the property no Western-built tool has prioritised, and the reason the comparator guidelines in every major chatbot evaluation to date are ACOG, RCOG, WHO, or European societies rather than any Indian source.

4. Uncertainty is surfaced, not smoothed. Where evidence conflicts, the tool should say so. Adjuvant decisions in early-stage endometrial cancer, timing of delivery in growth restriction, and HPV triage strategies all carry live disagreement between bodies. A 2025 Communications Medicine study showed general LLMs do the opposite under pressure: presented with fabricated clinical details, they elaborate confidently rather than flag the inconsistency.

5. Answers are retrieval-grounded. This is the load-bearing property, because it produces the other four. Systems that retrieve from an indexed, curated corpus and then synthesise can only cite what exists, can be updated when guidelines change, and can hold multiple jurisdictions in the corpus simultaneously. The measured effect is large and repeatable: pooled OR 1.35 for accuracy across 20 studies (JAMIA, 2025); 43 to 99 percent accuracy when hepatology guidelines were supplied as structured context; hallucinations eliminated in a controlled radiology comparison.

6. The trail is auditable. After the consultation, the clinician should be able to reconstruct why the tool said what it said: question, sources retrieved, synthesis. This matters medicolegally in a jurisdiction where accountability for the decision stays with the registered medical practitioner, and it matters practically for departmental protocol committees deciding whether a tool is deployable.

The Six Properties as a Bedside Checklist

What This Looks Like in Indian OBGYN Practice

Consider three ordinary weeks in practice.

A consultant in a Tier 2 city is updating the department’s cervical screening SOP. The evidence question is not "what does ACOG recommend"; it is "what do FOGSI GCPR and NCG resource-stratified guidance recommend for our setting, where does WHO 2021 differ, and what does the colposcopy referral pathway look like if we adopt primary HPV testing with the lab capacity we actually have." A decision-support tool that cannot hold FOGSI, NCG, and WHO in the same answer, with versions and citations, is not supporting this decision. The gaps in US-built evidence tools for Indian practice are documented in more detail elsewhere in this series.

A registrar on a night shift needs the magnesium sulphate regimen and the recurrence-of-seizure protocol. The correct behaviour of an evidence tool here is speed, the exact national protocol, the source, and nothing else. Confidence without a citation is precisely what the registrar’s seniors have trained her to distrust in juniors; the standard for software should not be lower.

A fertility specialist counselling on letrozole versus clomiphene wants the trial evidence, the guideline positions, and the CDSCO-relevant availability picture in one place. The evidence exists in ten tabs; decision support means retrieving and synthesising it with the disagreements left visible.

OneRX, an AI clinical decision support platform for doctors, is built against exactly these six properties: retrieval-grounded synthesis from current guidelines and primary literature, Indian sources indexed alongside international ones, citations that resolve, and the clinical decision left where Indian law and good practice put it, with the clinician. The claim worth making is not that any platform is infallible; it is that these properties are checkable, and clinicians should check them, for OneRX and for every competing tool.

How to Evaluate Any Tool This Quarter

• Pick three questions from your own last month of practice: one screening protocol, one drug-in-pregnancy query, one guideline-divergence question.
• Put them to the tool and score against the six properties in the table above.
• Disqualify on property 1 alone: a tool whose citations do not resolve has no floor under any other answer it gives.
• Re-test after major guideline revisions; a tool that still quotes the superseded version fails property 2 permanently, because the failure will recur at every revision cycle.
• For the questions you will still put to a general chatbot, apply a task-level framework for safe chatbot use rather than a blanket rule.

Frequently Asked Questions

What is AI clinical decision support in gynaecology?

Software that retrieves, synthesises, and presents medical evidence (guidelines, trials, drug information) to support a clinician’s decision at the point of care. It is distinct from diagnostic AI (such as image classifiers) and from general chatbots, which generate answers from training data rather than retrieving from a curated evidence corpus.

How is a clinical decision support platform different from ChatGPT?

Architecture and accountability. A decision-support platform answers by retrieval from an indexed, versioned evidence base and shows its sources; a general chatbot answers from parametric memory, which produces the documented citation-fabrication and outdated-guideline failure modes. The measured accuracy gain from retrieval grounding is significant (pooled OR 1.35; JAMIA, 2025).

Do Indian regulations allow AI decision support in OBGYN?

AI decision-support tools operate in India under a developing framework spanning medical device rules, data protection law, and professional accountability norms; responsibility for clinical decisions remains with the registered medical practitioner. Tools positioned as evidence synthesis for clinicians, rather than autonomous diagnosis, sit most comfortably within that framework. (See our full analysis of medical AI regulation in India.)

Which guidelines should an evidence platform index for Indian gynaecology?

At minimum: FOGSI GCPRs, NCG resource-stratified guidance, ICMR recommendations, national programme protocols (including the DIPSI-based GDM protocol), WHO guidance, and the major international bodies (ACOG, RCOG, FIGO, ESGO) with jurisdiction clearly labelled on every answer.

Can retrieval-grounded AI still be wrong?

Yes. Retrieval reduces fabrication and staleness; it does not abolish synthesis errors, and no property replaces clinical judgement. The point of the six properties is that a grounded, cited, dated, auditable answer can be verified in seconds, while an ungrounded answer can only be believed or disbelieved.

Conclusion

Evidence-based, applied to medical AI, should be a claim that survives testing. In obstetrics and gynaecology, where guidance is plural by design and Indian recommendations diverge from Western defaults for good reasons, the six properties give clinicians a way to test it: resolving citations, dated versions, jurisdiction awareness, surfaced uncertainty, retrieval grounding, and an auditable trail. The published evidence says grounding is what moves accuracy, and the Indian evidence gap says jurisdiction awareness is where tools for this market will be won or lost. Apply the checklist to every tool that wants a place in your consulting room, this platform included.